Drug Profile
Cytomegalovirus immune globulin - Shanxi Kangbao Biological Product
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Shanxi Kangbao Biological Product
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cytomegalovirus infections(Prevention) in China (IV)
- 15 Jan 2016 Early research in Cytomegalovirus infections (Prevention) in China (IV) prior to January 2016 (Shanxi Kangbao Biological Product pipeline, January 2016)